Miragon
Generic Name
Mirabegron
Manufacturer
Astellas Pharma Inc. (Original)
Country
Japan
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| miragon 25 mg tablet | ৳ 30.00 | ৳ 300.00 |
Description
Overview of the medicine
Miragon (Mirabegron) is a medication used to treat symptoms of overactive bladder (OAB), such as urinary urgency, frequency, and urge incontinence. It works by relaxing the bladder muscle to increase bladder capacity.
Uses & Indications
Dosage
Adults
The recommended starting dose is 25 mg orally once daily. The dose may be increased to 50 mg orally once daily based on individual patient efficacy and tolerability.
Elderly
No dose adjustment is required for elderly patients.
Renal_impairment
For mild to moderate renal impairment (CrCl 30-89 mL/min), no dose adjustment for 25 mg. For severe renal impairment (CrCl 15-29 mL/min), the maximum dose is 25 mg once daily. Not recommended for end-stage renal disease (CrCl <15 mL/min) or patients on hemodialysis.
How to Take
Take Miragon orally once daily with or without food. Swallow the tablet whole with water; do not chew, crush, or divide it.
Mechanism of Action
Mirabegron is a beta-3 adrenergic agonist that selectively activates beta-3 adrenergic receptors in the bladder detrusor muscle. This activation leads to relaxation of the detrusor muscle during the urine storage phase, increasing bladder capacity and reducing bladder contractions, thereby alleviating OAB symptoms.
Pharmacokinetics
Onset
Clinical effects may be observed within 8 weeks of treatment initiation.
Excretion
Approximately 55% of the dose is excreted renally (25% as unchanged drug), and 34% is excreted in feces.
Half life
The elimination half-life is approximately 32 hours for the 25 mg dose.
Absorption
Mirabegron is slowly absorbed after oral administration, with peak plasma concentrations (Tmax) occurring at approximately 3.5 to 4 hours. Absolute bioavailability is approximately 29% for the 25 mg dose.
Metabolism
Mirabegron is metabolized by multiple pathways including CYP2D6, CYP3A4, butyrylcholinesterase, and uridine diphospho-glucuronosyltransferases (UGT).
Side Effects
Contraindications
- Uncontrolled severe hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg)
Drug Interactions
Digoxin
Mirabegron is a moderate CYP2D6 inhibitor. Co-administration with Digoxin (a P-gp substrate) may increase Digoxin exposure; monitor Digoxin levels.
Metoprolol
Co-administration may increase Metoprolol exposure; dose adjustment of Metoprolol may be necessary.
Desipramine
May increase desipramine levels.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
Overdose symptoms may include palpitations, increased heart rate, and increased blood pressure. Treatment should be symptomatic and supportive.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended during breastfeeding as it is excreted in breast milk.
Side Effects
Contraindications
- Uncontrolled severe hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg)
Drug Interactions
Digoxin
Mirabegron is a moderate CYP2D6 inhibitor. Co-administration with Digoxin (a P-gp substrate) may increase Digoxin exposure; monitor Digoxin levels.
Metoprolol
Co-administration may increase Metoprolol exposure; dose adjustment of Metoprolol may be necessary.
Desipramine
May increase desipramine levels.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
Overdose symptoms may include palpitations, increased heart rate, and increased blood pressure. Treatment should be symptomatic and supportive.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended during breastfeeding as it is excreted in breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by FDA/DGDA
Patent Status
Generically available
Clinical Trials
Mirabegron has undergone extensive clinical trials demonstrating its efficacy and safety in treating overactive bladder symptoms. Trials have shown significant improvements in urinary frequency, urgency, and incontinence episodes compared to placebo.
Lab Monitoring
- Monitor blood pressure regularly, especially in patients with pre-existing hypertension or cardiovascular disease.
Doctor Notes
- Assess blood pressure before and during treatment, particularly in patients with a history of hypertension.
- Evaluate for symptoms of bladder outlet obstruction or severe renal/hepatic impairment prior to initiation.
- Advise patients on the importance of adherence to the once-daily dosing regimen.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not chew, crush, or break the tablet.
- Inform your doctor if you experience any severe side effects or changes in blood pressure.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Miragon is not known to affect the ability to drive or operate machinery. However, if you experience dizziness, avoid such activities.
Lifestyle Advice
- Maintain a healthy fluid intake as advised by your doctor.
- Consider bladder training techniques along with medication for better management of OAB.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.